MorphoSys AG - ESG Rating & Company Profile powered by AI
If you work at MorphoSys AG and you would like to use your ESG aseessment, please get in touch. The ESG rating includes seventeen United Nations SDGs including: 'Affordable & Clean Energy', 'Climate Action' and 'Peace, Justice & Strong Institutions'. This assessment of MorphoSys AG was assembled by All Street Sevva using cutting edge AI.
MorphoSys AG in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | MorphoSys AG | 8.0 | High |
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does MorphoSys AG have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes MorphoSys AG disclose current and historical energy intensity?
Sign up for free to unlockDoes MorphoSys AG report the average age of the workforce?
Sign up for free to unlockDoes MorphoSys AG reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes MorphoSys AG disclose its ethnicity pay gap?
Sign up for free to unlockDoes MorphoSys AG disclose cybersecurity risks?
Sign up for free to unlockDoes MorphoSys AG offer flexible work?
Sign up for free to unlockDoes MorphoSys AG have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes MorphoSys AG disclose the number of employees in R&D functions?
Sign up for free to unlockDoes MorphoSys AG conduct supply chain audits?
Sign up for free to unlockDoes MorphoSys AG disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes MorphoSys AG conduct 360 degree staff reviews?
Sign up for free to unlockDoes MorphoSys AG disclose the individual responsible for D&I?
Sign up for free to unlockDoes MorphoSys AG disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes MorphoSys AG disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes MorphoSys AG disclose water use targets?
Sign up for free to unlockDoes MorphoSys AG have careers partnerships with academic institutions?
Sign up for free to unlockDid MorphoSys AG have a product recall in the last two years?
Sign up for free to unlockDoes MorphoSys AG disclose incidents of discrimination?
Sign up for free to unlockDoes MorphoSys AG allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas MorphoSys AG issued a profit warning in the past 24 months?
Sign up for free to unlockDoes MorphoSys AG disclose parental leave metrics?
Sign up for free to unlockDoes MorphoSys AG disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes MorphoSys AG disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes MorphoSys AG disclose the pay ratio of women to men?
Sign up for free to unlockDoes MorphoSys AG support suppliers with sustainability related research and development?
Sign up for free to unlockDoes MorphoSys AG disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes MorphoSys AG reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs MorphoSys AG involved in embryonic stem cell research?
Sign up for free to unlockDoes MorphoSys AG disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes MorphoSys AG disclose its waste policy?
Sign up for free to unlockDoes MorphoSys AG report according to TCFD requirements?
Sign up for free to unlockDoes MorphoSys AG disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes MorphoSys AG disclose energy use targets?
Sign up for free to unlockDoes MorphoSys AG disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes MorphoSys AG have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for MorphoSys AG
These potential risks are based on the size, segment and geographies of the company.
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.